Navigation Links
DRAXIS Health Reports Fourth Quarter and Year End Results
Date:2/7/2008

r

demand. The lower than expected volumes from Genzyme have offset the

positive impact of increased volumes related to new business

activities taking place during 2007 within our contract

manufacturing division. We believe that the trend is for Hectorol(R)

volumes to ultimately be phased out during 2009. We also anticipate

quarterly fluctuations in volume which may not be predictable.

- The contract manufacturing segment began to implement procedures,

including organizational changes, to reduce production delays that

have in the past resulted in shipments not being released in a

timely manner impacting quarterly results for most of 2007.

While short-term financial performance for 2007 was below the Company's expectations, the Company did achieve significant key milestones consistent with the sources of future growth for the Company in future years.

Guidance for Future Years

The Company expects progressively improving financial results during 2008 compared to 2007 as a result of increased demand through new business opportunities, product introductions and additional contracts. This is expected to result in continuing year-over-year growth in revenues, operating income, and cash flows going forward, starting from a base in 2008. Net earnings per share for 2008 are expected to increase significantly over 2007. However, the extent to which the Company can reasonably predict the financial performance for 2008 is limited due to variables outside of the control of the Company. Accordingly, the Company does not plan to provide specific quantitative guidance given the anticipated period of expansion and significant growth that is expected to be accompanied by periods of increased forecast variability due to several factors, including the following:

- The timing and ramping up of commercial production of non-sterile

prod
'/>"/>

SOURCE DRAXIS Health Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. Draxis Health selected by Johnson and Johnson Consumer Companies, Inc. for major contract manufacturing relationship
2. DRAXIS to Present at the 2007 UBS Global Life Sciences Conference
3. DRAXIS Health Inc. Announces Retirement of Dr. Martin Barkin as President and Chief Executive Officer
4. DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA
5. DRAXIS Announces Application for Normal Course Issuer Bid
6. DRAXIS Share Buyback Approved by TSX
7. DRAXIS to Report Fourth Quarter and Year End 2007 Results on February 7th
8. Penn study finds pro-death proteins required to regulate healthy immune function
9. UCLA researchers identify markers that may predict diabetes in still-healthy people
10. Air pollution linked to cardiovascular risk indices in healthy young adults
11. More proof needed of safety and quality of electronic personal health records
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... York, NY (PRWEB) September 19, 2014 ... over the five years to 2014. Industry operators were ... time during the period, as well as establish distribution ... is due in large part to its novelty; energy ... Nevertheless, in that time, industry operators have been able ...
(Date:9/19/2014)... MD & Salt Lake City, UT (PRWEB) September 19, ... to launch the new Activz Greens Smoothie ... Products Expo East, September 18th-20th in Baltimore, MD. ... with 8 organic super foods combined in one convenient ... Natural Products Expo East, September 18th-20th in Baltimore, MD. ...
(Date:9/19/2014)... (SALT LAKE CITY)A new study by researchers at the ... a longstanding question about the role of mitochondria in ... a new mouse model to study such illnesses. ... Ph.D., professor of biochemistry, found that when healthy, functioning ... fibers that conduct electricity away from neurons mice ...
(Date:9/19/2014)... as Johne,s disease, is caused by the bacterium ... Austria, there is a legal obligation to report ... treatment-resistant diarrhoea and wasting among affected animals. The ... farms. The animals produce less milk, exhibit fertility ... such as udder inflammation. , To date ...
(Date:9/19/2014)... 19, 2014 Lifeinsure.biz has released ... riders that can be purchased without medical examinations. ... and make a life insurance policy more advantageous. Clients ... more about extra options available for a no medical ... medical examinations required is simple to purchase, however it ...
Breaking Medicine News(10 mins):Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Relaxation Drink Production in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 2Health News:New Activz Greens Smoothie with 8 Organic Superfoods & More Launched at Natural Products Expo East 3Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 2Health News:Mouse model sheds light on role of mitochondria in neurodegenerative diseases 3Health News:Lymphatic fluid used for first time to detect bovine paratuberculosis 2Health News:No Medical Exam Life Insurance - Lifeinsure.biz Presents 5 Important Riders! 2
... found to be the combination of dry eyes and mouth//, ... symptoms include dry, gritty or burning eyes, intermittent blurry vision, ... enlarged parotid glands. The parotids are a pair of salivary ... Other signs and symptoms may include dry skin or vaginal ...
... treatments has been accused of placing money before patients//, ... drug. <BR.,Patients suffering from cancer linked to asbestos will ... is pemetrexed disodium, after a study conducted ... ,The group analyzed the cost effectiveness of the ...
... new fat-busting laser treatment called SmartLipo. It is to be ... less invasive form of liposuction//. It removes unsightly lumps of fat ... About six cosmetic surgery clinics in London, the Midlands and the ... Food and Drug Administration (FDA) has not approved to the procedure ...
... investigators at John Hopkins Children’s Center//, patient’s safety system can ... errors into a computer database. ,Hopkins researchers ... reporting on the errors voluntarily plus steps taken to overcome ... not new, but few studies have looked at the accuracy ...
... commercial production at its Dehradun unit. // ,The ... pharmacuetical formulations unit would achieve a capacity level of 300 ... in stages., ,Plans of establishing a parenterals division at ... the company was trading at Rs 102.35, down 4.48 per ...
... have died after catching bird flu from wild swans//. ... said that they had occurred earlier this year. They also went ... avian flu that were being passed on from the wild birds. ... a village in Azerbaijan, and are believed to have caught the ...
Cached Medicine News:Health News:Voluntary Error-Reporting System Ensures Patient Safety 2Health News:Voluntary Error-Reporting System Ensures Patient Safety 3Health News:Voluntary Error-Reporting System Ensures Patient Safety 4Health News:Four Deaths Due To Bird Flu Caught From Wild Birds 2
(Date:9/19/2014)... Fla. , Sept. 19, 2014  The body ... with the publication of two papers this past week.  ... – Head and Neck Surgery , finds that ... and subjective measures of sleep disordered breathing, leading the ... reduction in obstructive sleep apnea severity and improvement of ...
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/19/2014)... 2014 Reductions in kidney failure ... in people with diabetes type 2 "Intensive ... for the kidneys." Australian researchers have discovered ... diabetes leads to persistent reductions in kidney failure many ... global study has found that, five and a half ...
Breaking Medicine Technology:New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3
... SAN DIEGO, Jan. 7 Trius Therapeutics, Inc. ... clinical trial of TR-701, an,antibacterial drug candidate intended ... including those caused by MRSA,and other drug-resistant strains. ... will test tolerability, safety and,pharmacokinetics of the oral ...
... Ill., Jan. 7 Baxter International,Inc. (NYSE: ... pre-clinical,programs to develop recombinant Factor IX proteins to ... recombinant Factor IX therapy for,treatment of acute bleeding ... Factor IX therapy for prophylaxis of bleeding in,hemophilia ...
Cached Medicine Technology:Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3
For the quantitative in vitro determination of Apolipoprotein A-1 in human serum....
For the quantitative in vitro determination of apolipoprotein A-1 (apo A-1) in serum and plasma. For use as an aid if assessing the risk of coronary artery disease....
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
The GGT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of g-glutamyl transferase activity in serum and plasma...
Medicine Products: